Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Inhibikase Therapeutics initiated with a Buy at JonesTrading » 09:11
07/15/21
07/15
09:11
07/15/21
09:11
IKT

Inhibikase Therapeutics

$2.45 /

-0.17 (-6.49%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy initiated coverage of Inhibikase Therapeutics with a Buy rating and $12 price target. Inhibikase is a clinical stage company developing a brain penetrant c-Abl kinase inhibitor for the treatment of Parkinson's disease, Roy tells investors in a research note. Citing the "current low implied valuation" of Inhibikase and a potential four-times takeover multiple on adjusted peak sales of $1.8B, the analyst views the stock as "well undervalued."

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$2.45 /

-0.17 (-6.49%)

IKT Inhibikase Therapeutics
$2.45 /

-0.17 (-6.49%)

04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
  • 28
    Oct
IKT Inhibikase Therapeutics
$2.45 /

-0.17 (-6.49%)

Over a month ago
On The Fly
Fly Intel: Pre-market Movers » 08:53
06/16/21
06/16
08:53
06/16/21
08:53
SPI

SPI Energy

$6.57 /

-0.19 (-2.81%)

, KIN

Kindred Biosciences

$6.35 /

+0.31 (+5.13%)

, ELAN

Elanco

$34.83 /

+1.33 (+3.97%)

, MNKD

MannKind

$4.11 /

-0.02 (-0.48%)

, ARVL

Arrival

$19.90 /

+1.14 (+6.08%)

, FORD

Forward Industries

$2.73 /

-0.15 (-5.21%)

, CNTG

Centogene

$10.25 /

-0.31 (-2.94%)

, ORCL

Oracle

$81.64 /

-0.95 (-1.15%)

, MX

MagnaChip

$25.64 /

-0.2 (-0.77%)

, BNTX

BioNTech

$217.98 /

-2 (-0.91%)

, IKT

Inhibikase Therapeutics

$4.03 /

-0.825 (-16.99%)

, RBLX

Roblox

$89.80 /

+2.02 (+2.30%)

Check out this morning's…

ShowHide Related Items >><<
SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MX MagnaChip
$25.64 /

-0.2 (-0.77%)

MNKD MannKind
$4.11 /

-0.02 (-0.48%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

FORD Forward Industries
$2.73 /

-0.15 (-5.21%)

CNTG Centogene
$10.25 /

-0.31 (-2.94%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

05/12/21 Alliance Global Partners
Kindred Biosciences price target raised to $15.25 from $9.25 at Alliance Global
12/24/20 Barclays
Kindred atopic dermatitis portfolio could net $130M in sales, says Barclays
12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
ELAN Elanco
$34.83 /

+1.33 (+3.97%)

06/15/21 Cleveland Research
Elanco upgraded to Neutral from Underperform at Cleveland Research
05/17/21 Citi
Elanco price target raised to $42 from $39 at Citi
05/11/21 Gabelli
Elanco upgraded to Buy from Hold at Gabelli
05/11/21 Barclays
Elanco upgraded to Equal Weight from Underweight at Barclays
MNKD MannKind
$4.11 /

-0.02 (-0.48%)

05/13/21 RBC Capital
MannKind initiated with a Sector Perform at RBC Capital
02/26/21 H.C. Wainwright
MannKind price target raised to $6.50 from $2.50 at H.C. Wainwright
02/24/21 BTIG
MannKind price target raised to $8 from $4 at BTIG
12/29/20 BTIG
United Therapeutics' treprostinil development uses MannKind technology, say BTIG
ARVL Arrival
$19.90 /

+1.14 (+6.08%)

06/03/21 Barclays
Arrival initiated with an Overweight at Barclays
04/05/21 Cowen
Cowen starts Arrival at Outperform on 'unique microfactory approach'
04/05/21 Cowen
Arrival initiated with an Outperform at Cowen
FORD Forward Industries
$2.73 /

-0.15 (-5.21%)

CNTG Centogene
$10.25 /

-0.31 (-2.94%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
ORCL Oracle
$81.64 /

-0.95 (-1.15%)

06/16/21 Morgan Stanley
Oracle shares likely range-bound until visibility improves, says Morgan Stanley
06/16/21 Jefferies
Oracle price target raised to $80 from $75 at Jefferies
06/16/21 Monness Crespi
Monness Crespi would be buyers of Oracle on any post-earnings weakness
06/16/21 JPMorgan
Oracle price target raised to $77 from $73 at JPMorgan
MX MagnaChip
$25.64 /

-0.2 (-0.77%)

03/30/21 Vertical Group
MagnaChip downgraded to Neutral from Buy at Vertical Group
03/04/21 Needham
Needham revises view on MagnaChip SOTP value to $41-$46 per share
03/04/21 Needham
MagnaChip could be worth $39-$45 per share in a deal, says Needham
02/23/21 Citi
MagnaChip price target raised to $20 from $19 at Citi
BNTX BioNTech
$217.98 /

-2 (-0.91%)

06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
05/18/21 Goldman Sachs
BioNTech initiated with a Neutral at Goldman Sachs
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
RBLX Roblox
$89.80 /

+2.02 (+2.30%)

06/16/21 Morgan Stanley
Morgan Stanley lowers Q2 estimates for Roblox, says long-term view unchanged
06/16/21 JPMorgan
Roblox shares likely range-bound after May metrics, says JPMorgan
06/16/21 Stifel
Roblox May KPIs 'probably not enough' to sustain shares' momentum, says Stifel
06/01/21 Truist
Roblox price target raised to $103 from $83 at Truist
RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MX MagnaChip
$25.64 /

-0.2 (-0.77%)

MNKD MannKind
$4.11 /

-0.02 (-0.48%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

CNTG Centogene
$10.25 /

-0.31 (-2.94%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

  • 16
    Jun
  • 01
    Dec
  • 28
    Oct
  • 01
    Oct
  • 23
    Jul
  • 10
    Jul
RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MX MagnaChip
$25.64 /

-0.2 (-0.77%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

FORD Forward Industries
$2.73 /

-0.15 (-5.21%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MNKD MannKind
$4.11 /

-0.02 (-0.48%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

Syndicate
Inhibikase Therapeutics 15M share Secondary priced at $3.00 » 19:47
06/15/21
06/15
19:47
06/15/21
19:47
IKT

Inhibikase Therapeutics

$4.03 /

-0.825 (-16.99%)

The deal priced below…

The deal priced below last closing price of $4.04. ThinkEquity is acting as sole book running manager for the offering.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 28
    Oct
IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

Syndicate
Inhibikase Therapeutics files to sell 8M shares of common stock  16:26
06/11/21
06/11
16:26
06/11/21
16:26
IKT

Inhibikase Therapeutics

$6.01 /

-0.17 (-2.75%)

 
ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$6.01 /

-0.17 (-2.75%)

IKT Inhibikase Therapeutics
$6.01 /

-0.17 (-2.75%)

04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 28
    Oct
IKT Inhibikase Therapeutics
$6.01 /

-0.17 (-2.75%)

Initiation
Inhibikase Therapeutics initiated with a Buy at ThinkEquity » 07:25
04/26/21
04/26
07:25
04/26/21
07:25
IKT

Inhibikase Therapeutics

$5.99 /

+0.11 (+1.87%)

ThinkEquity initiated…

ThinkEquity initiated coverage of Inhibikase Therapeutics with a Buy rating and $15 price target.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$5.99 /

+0.11 (+1.87%)

  • 28
    Oct
IKT Inhibikase Therapeutics
$5.99 /

+0.11 (+1.87%)

Over a quarter ago
Conference/Events
Inhibikase Therapeutics participates in a conference call with Truist » 09:55
04/06/21
04/06
09:55
04/06/21
09:55
IKT

Inhibikase Therapeutics

$6.11 /

+0.01 (+0.16%)

Conference call with…

Conference call with management will be held on April 6 at 10 am hosted by Truist.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$6.11 /

+0.01 (+0.16%)

  • 28
    Oct
IKT Inhibikase Therapeutics
$6.11 /

+0.01 (+0.16%)

Conference/Events
Inhibikase Therapeutics participates in a conference call with Truist » 04:55
04/06/21
04/06
04:55
04/06/21
04:55
IKT

Inhibikase Therapeutics

$6.11 /

-0.34 (-5.27%)

Conference call with…

Conference call with management will be held on April 6 at 10 am hosted by Truist.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$6.11 /

-0.34 (-5.27%)

  • 28
    Oct
IKT Inhibikase Therapeutics
$6.11 /

-0.34 (-5.27%)

Conference/Events
Inhibikase Therapeutics participates in a conference call with Truist » 11:33
03/31/21
03/31
11:33
03/31/21
11:33
IKT

Inhibikase Therapeutics

$5.97 /

+0.17 (+2.93%)

Conference call with…

Conference call with management will be held on April 6 at 10 am hosted by Truist.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$5.97 /

+0.17 (+2.93%)

  • 28
    Oct
IKT Inhibikase Therapeutics
$5.97 /

+0.17 (+2.93%)

Hot Stocks
Inhibikase Therapeutics announces first patients dosed in IkT-148009 » 08:12
02/17/21
02/17
08:12
02/17/21
08:12
IKT

Inhibikase Therapeutics

$7.12 /

-0.09 (-1.25%)

Inhibikase Therapeutics…

Inhibikase Therapeutics announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. This randomized Phase 1 study is investigating the safety, tolerability and pharmacokinetics, PK,of IkT-148009 in healthy volunteers aged 45 to 70 years old with the objective of identifying the maximum tolerated dose and the PK profile of IkT-148009 in single and multiple ascending dose settings. In preclinical animal models of progressive disease, the Company demonstrated that once a day oral therapy with IkT-148009 can both halt and reverse functional loss in the brain and gastrointestinal tract. "The initiation of our Phase 1 study of IkT-148009 for the treatment of Parkinson's disease represents a significant milestone for Inhibikase. Based on preclinical data, we believe that c-Abl plays a critical role in the Parkinson's disease process and inhibition of c-Abl represents a promising new approach to disease modification," stated Milton Werner, Ph.D., Chief Executive Officer of Inhibikase Therapeutics. "We are excited to advance into the clinic, and believe that IKT-148009 could be a transformative therapy for millions of patients worldwide."

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$7.12 /

-0.09 (-1.25%)

  • 28
    Oct
IKT Inhibikase Therapeutics
$7.12 /

-0.09 (-1.25%)

General news
Inhibikase Therapeutics granted patent for inhibiting kinases » 12:33
02/02/21
02/02
12:33
02/02/21
12:33
IKT

Inhibikase Therapeutics

$7.60 /

+0.24 (+3.26%)

Shares of Inhibikase…

Shares of Inhibikase Therapeutics moved higher after the United States Patent and Trademark Office posted on its website a patent granted to the company for "compositions and methods for inhibiting kinases." The stock in midday trading is up 20%, or $1.47, to $8.77. Reference Link

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$7.60 /

+0.24 (+3.26%)

  • 28
    Oct
IKT Inhibikase Therapeutics
$7.60 /

+0.24 (+3.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.